Financial Assistance | ADCIRCA (tadalafil) tablets Once-daily treatment for PAH

Once your benefits have been verified, if you find yourself in need of financial assistance, you may qualify for one of the various programs offered by United Therapeutics. It is important to notify your Specialty Pharmacy (SP) when you are scheduling the shipment of your medication or you can contact United Therapeutics Cares directly for more comprehensive information on available options.

ADCIRCA Co-Pay Assistance Card

For patients who have commercial or private insurance plans, we offer a co-pay assistance card specifically designed to help cover a portion of your out-of-pocket expenses related to obtaining ADCIRCA. This initiative aims to mitigate the financial burden on patients, making treatment more accessible.

Most eligible patients with commercial or private insurance may only need to pay a co-pay of as little as $0 for each prescription of Adcirca, with the potential to receive benefits up to a monthly coverage limit of $800, allowing for a more manageable approach to their healthcare costs.

Terms and Conditions

*Patients seeking assistance must meet specific eligibility criteria to qualify for these programs. It is important to note that patients receiving reimbursement through federal or state programs such as Medicare, Medicaid, VA, DoD (TRICARE), or Indian Health Services may not be eligible for certain types of assistance. Additionally, some aspects of this patient assistance may be managed by third-party organizations dedicated to patient support. Be aware that the Program may be subject to additional state law restrictions and those residing in select states may not qualify for the Program. Specifically, Massachusetts residents, as well as certain California residents, may face restrictions in their eligibility.

Patient Assistance Program (PAP)

United Therapeutics also offers a free medication program dedicated to uninsured and underinsured patients who fulfill the necessary eligibility requirements. This program is aimed at ensuring that financial limitations do not prevent individuals from accessing essential medications.

Call United Therapeutics Cares at 1-844-864-8437 to find out if you qualify for financial support or visit UnitedTherapeuticsCares.com for more information on how to enroll and receive assistance.

Important Safety Considerations for ADCIRCA® (tadalafil)

• It is crucial to discuss your complete medical history, including all medical conditions and medications you are currently taking, with your healthcare provider before you begin treatment with ADCIRCA. This will help ensure that you receive safe and effective treatment tailored to your needs.
• Do not take ADCIRCA if you are currently using any medications that contain nitrates (commonly prescribed for chest pain) or guanylate cyclase stimulators, as the combination of these medications could lead to a sudden and dangerous drop in blood pressure.
• You should not use ADCIRCA if you have a known allergy to tadalafil or any other ingredient included in ADCIRCA, as this could lead to serious allergic reactions.
• ADCIRCA belongs to a medication class known as phosphodiesterase 5 inhibitors (PDE-5i) which work by causing blood vessels to widen, potentially leading to a decrease in blood pressure. If you have a history of heart disease or issues with low blood pressure, it is essential to inform your healthcare provider prior to starting ADCIRCA, as these conditions can be affected by the medication's action.
• It is advisable to talk to your healthcare provider if you are pregnant, planning to become pregnant, breastfeeding, or intending to breastfeed, as the effects of ADCIRCA on these circumstances need to be carefully evaluated.
• If you have previously experienced obstruction in the veins of your lungs, known medically as pulmonary veno-occlusive disease (PVOD), ADCIRCA is not recommended for you due to the potential for adverse effects.
• Combining ADCIRCA with alcohol or blood pressure medications such as alpha-blockers may lead to reduced blood pressure and may result in symptoms of hypotension, including light-headedness or fainting, which should be monitored closely.
• It is advised not to take ADCIRCA if you are currently using rifampin (an antibiotic for certain bacterial infections) or antifungal treatments such as ketoconazole and itraconazole. If you need to be treated with both ADCIRCA and ritonavir (Norvir^®) simultaneously, your healthcare provider will need to adjust your ADCIRCA dosage accordingly. Notify your healthcare provider if you have any kidney or liver issues prior to beginning treatment with ADCIRCA.
• Be aware that ADCIRCA contains the same active ingredient (tadalafil) as Cialis^®, which is commonly prescribed for erectile dysfunction (ED, impotence) and the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate). If you are taking ADCIRCA, you should not also take Cialis or other PDE-5 inhibitors concurrently, as this may lead to potential health risks.
• Although rare, some patients have reported experiencing side effects such as decreased eyesight or loss of vision in one or both eyes (NAION), or a sudden decrease or loss of hearing, sometimes accompanied by ringing in the ears and dizziness. Should you experience any of these side effects after taking ADCIRCA, it is crucial to seek medical attention immediately to address any serious health concerns.
• In extremely rare instances, men using PDE-5 inhibitors (including tadalafil) for erectile dysfunction have reported side effects such as an erection lasting longer than four hours, which is known as priapism. If you encounter a prolonged erection, it is vital to seek emergency medical attention promptly to avoid potential complications.
• The most commonly reported side effects associated with ADCIRCA include headache, muscle pain, flushing (getting red or hot in the face), nausea, discomfort in the arms, legs, or back, upset stomach, and congestion in the nasal passages, which should be monitored and discussed with your healthcare provider if they persist.

ADC.ISI.CON.SEP2020

For more comprehensive information regarding ADCIRCA, please refer to the Full Prescribing Information and Patient Information or contact us directly at 1-800-545-5979 for personalized support.

To report any negative side effects, contact your healthcare provider or the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088. Your health and safety are our top priorities, and we encourage open communication about any concerns you may have.